Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects (Q37770171)

22 August 2017

1 reference

title

Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects (English)

1 reference

22 August 2017

Shin-ichiro Miura

1

1 reference

22 August 2017

Sadashiva S Karnik

series ordinal

2

1 reference

22 August 2017

Keijiro Saku

series ordinal

3

1 reference

22 August 2017

5 July 2010

1 reference

Journal of the Renin-Angiotensin-Aldosterone System

22 August 2017

1 reference

22 August 2017

12

1 reference

22 August 2017

1

1 reference

22 August 2017

1-7

1 reference

Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

High constitutive activity of native H3 receptors regulates histamine neurons in brain.

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

International union of pharmacology. XXIII. The angiotensin II receptors

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Angiotensin II receptors and angiotensin II receptor antagonists.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Interaction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Mechanism of constitutive activation of the AT1 receptor: influence of the size of the agonist switch binding residue Asn(111).

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Comparison of the antagonistic effects of different angiotensin II receptor blockers in human coronary arteries

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3891529

Proposal of a New Binding Orientation for Non-Peptide AT1 Antagonists: Homology Modeling, Docking and Three-Dimensional Quantitative Structure−Activity Relationship Analysis

1 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1177%2F1470320310370852

Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor

21 January 2018

1 reference

12 December 2020

Do valsartan and losartan have the same effects in the treatment of coronary artery disease?

1 reference

12 December 2020

Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan

1 reference

12 December 2020

Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy

1 reference

12 December 2020

A non-competitive type of angiotensin-receptor antagonism by losartan in renal artery preparations

1 reference

12 December 2020

Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms

1 reference

12 December 2020

The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism

1 reference

12 December 2020

In vivo pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for AT2 receptors

1 reference

12 December 2020

Mechanical stretch induces enhanced expression of angiotensin II receptor subtypes in neonatal rat cardiac myocytes

1 reference

12 December 2020

Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor

1 reference

12 December 2020

Identifiers

DOI

10.1177/1470320310370852

1 reference

22 August 2017

1 reference

22 August 2017

PubMed publication ID

20603272

1 reference